Literature DB >> 15017024

Cyclooxygenase-2 expression in the cornea of dogs with keratitis.

R S Sellers1, L Silverman, K N M Khan.   

Abstract

Cyclooxygenase-2 (COX-2) can be overexpressed at inflammatory sites, leading to the generation of proinflammatory prostanoids. Selective inhibitors of COX-2 have potential use in treating inflammatory conditions including ophthalmic diseases in veterinary medicine. Keratitis is considered the most common inflammatory eye disease in dogs. In this study we evaluated the expression of COX-2 in normal dog eyes and in dog eyes with keratitis by immunohistochemistry using isoform-specific antibodies. In the normal eye (n = 4), no COX-2 immunoreactivity was observed in the cornea. In keratitis, COX-2 (n = 12) expression was observed in all corneal layers (epithelium, stromal cells, and endothelium). COX-2 immunoreactivity was also noted in the stromal and epithelial cells of the iris and the stromal cells of the trabecular meshwork. These data indicate that COX-2 may play a pathophysiologic role in keratitis and suggest potential therapeutic implications of prostaglandin modulation in inflammatory eye diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15017024     DOI: 10.1354/vp.41-2-116

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  5 in total

1.  Molecular mechanism of the inhibition effect of Celecoxib on corneal collagen degradation in three dimensions.

Authors:  Wen-Song Zhang; Ji-Long Hao; Shuang Wang; Miao-Miao Bi; Hong Zhang; Hong-Yan Zhou
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

2.  Significance of arachidonic acid in ocular infections and inflammation.

Authors:  Trivendra Tripathi; Hassan Alizadeh
Journal:  Inflamm Cell Signal       Date:  2014

Review 3.  Significance of lipid mediators in corneal injury and repair.

Authors:  Sachidananda Kenchegowda; Haydee E P Bazan
Journal:  J Lipid Res       Date:  2009-11-03       Impact factor: 5.922

4.  Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension.

Authors:  Bruce I Gaynes; Anne Onyekwuluje
Journal:  Clin Ophthalmol       Date:  2008-06

5.  Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition.

Authors:  Heather L Chandler; Curtis A Barden; Ping Lu; Donna F Kusewitt; Carmen M H Colitz
Journal:  Mol Vis       Date:  2007-04-30       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.